FDAsafety guidance86% confidence
FDA AP — PADCEV (SUPPL)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (bladder cancer) as Astellas; the shared ADC mechanism makes the regulatory bar more directly transferable; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA761137. Sponsor: ASTELLAS. Submission status: AP. Submission type: SUPPL. Review priority: PRIORITY. Active ingredients: ENFORTUMAB VEDOTIN-EJFV.
Supporting Context
- Therapeutic area
- Oncology · ADC
- Sub-indication
- Bladder Cancer
Related signal: FDA grants priority review for PADCEV supplemental application